Floatz logo

Tinostamustine

Hodgkins Lymphoma

Mundipharma Research LimitedSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

150 Active assets in the Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB

View all 50 →

Same molecule, other indications

Tinostamustine is also rated in:

glioblastomaDormant
B
Indicative ·
58 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
soft tissue sarcomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →